The most frequently reported TEAEs (≥ 5 E/100 PY in any dose group) for patients receiving upadacitinib were elevated CPK, upper respiratory tract infection, and urinary tract infection (Supplemental Table 2). The gene discussed is PIK3C2A; the disease is Recurrent upper respiratory tract infections.